Last week, 29 Washington life science industry leaders sent a letter to Washington House Speaker Laurie Jinkins asking her to reject HB 1269 which would dramatically impact Washington’s nationally recognized life science industry and patient access to life-saving medications and therapies.
Proposed by Washington’s Healthcare Authority, this bill would remove protections for innovative medicines, rare disease drugs, and physician-administered drugs as well as legislative oversight and industry involvement in Washington’s Prescription Drug Advisory Board (PDAB), which was just created last year.
Without those protections, the PDAB would be in a position to make cutting-edge cancer therapies invented and manufactured in Washington inaccessible to Washingtonians, while putting our top 10 life science cluster at risk.
Contact your local legislators and urge them to oppose HB 1269. Click here to find your local legislators.